FDG-PET/CT combined with CTC might better ID new cancer cells

08/26/2010 | AuntMinnie.com (free registration)

Circulating tumor cell counts corresponded with results of FDG-PET/CT tests in determining nonprogressive or progressive disease in 78% of patients with bone metastases from breast cancer, a study published in the Journal of Nuclear Medicine showed. "The combination of FDG-PET/CT and CTC might be a useful tool to monitor response to therapy in patients without measurable extraosseous disease, especially in patients with elevated CTC at baseline," the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC